EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS

Huaxin Song iD, Xinjie Chen, Shujun Xiao, Jiaqi Wu, Yuting Dai iD, Wen Wu, Yu Wu iD, Xiangqin Weng, Jiachun Song, Ni Yan iD, Chenjing Ye, Fangfang Shi und 8 weitere

Science Translational Medicine · 12.08.2026 · 18 (862)

DOI: 10.1126/scitranslmed.ads9325 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, erschienen am 12.08.2026. Verfasst von Huaxin Song und 19 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: DNA Demethylation, Leukemia, Myeloid, Acute, Mutation, Myelodysplastic Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai, Noncommunicable Chronic Diseases National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia/myelodysplastic syndromes (AML/MDSs) carrying p53 mutations are refractory to various standard therapies. Arsenic trioxide (ATO) may be effective in restoring function to p53 structural mutants. Here, we report that mutant p53 rescued by ATO treatment strengthened interferon responses triggered by the DNA hypomethylating agent decitabine by transactivating interferon regulatory factor 7 ( IRF7 ) directly. Decitabine also increased the transactivation activity of ATO-rescued mutant p53 by inducing p53–serine-20 phosphorylation and blocking p53-inhibitory mouse double minute 2 homolog (MDM2). ATO and decitabine together killed p53-mutant AML cells and suppressed tumor growth in cell line–derived xenografts. In a first-in-human pilot clinical trial for testing the combination of ATO and decitabine (PANDA-T0 trial, NCT03855371), which enrolled five patients with AML/MDS harboring p53 structural mutations, the ATO and decitabine regimen produced manageable adverse events, and four of the five treated patients achieved complete remission at the level of the bone marrow, associated with p53 activation and interferon response. In 103 p53-mutant patients whose samples were deposited in Ruijin AML/MDS sample repository, 48 distinct p53 missense mutants were identified, 21 of which were classified as ATO and decitabine regimen applicable because of their competencies in activating p53 and interferon responses upon cotreatment. This study establishes an alternative treatment regimen for patients with p53-mutant AML/MDS and provides a proof-of-concept framework for p53-targeted therapy that differentiates between p53 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DemethylationLeukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesTumor Suppressor Protein p53AnimalsFemaleHumansMaleArsenic TrioxideArsenicalsAzacitidineCell Line, TumorDecitabineMice

Substanzen

Arsenic TrioxideArsenicalsAzacitidineDecitabineTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20…
  • Hematology Research Laboratory, West China Hospital, Department of Hematology, Sichuan University, Chengdu 610041, Sichuan, China.
  • School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.

ORCID-Profile: Huaxin Song, Yuting Dai, Yu Wu, Ni Yan, Sujiang Zhang, Jiale Wu, Min Lu

Förderung

  • National Natural Science Foundation of China
  • Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai
  • Noncommunicable Chronic Diseases National Science and Technology Major Project
  • the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China

Zitieren

APA

Song, H., Chen, X., Xiao, S., Wu, J., Dai, Y., Wu, W., Wu, Y., Weng, X., Song, J., Yan, N., Ye, C., Shi, F., Cui, J., Zheng, D., Zhang, H., Tan, K., Chen, X., Zhang, S., Wu, J., & Lu, M. (2026). Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS. Science Translational Medicine, 18(862). https://doi.org/10.1126/scitranslmed.ads9325

Vancouver

Song H, Chen X, Xiao S, Wu J, Dai Y, Wu W, et al. Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS. Science Translational Medicine. 2026;18(862). doi:10.1126/scitranslmed.ads9325

BibTeX
@article{Song2026,
  author = {Song, Huaxin and Chen, Xinjie and Xiao, Shujun and Wu, Jiaqi and Dai, Yuting and Wu, Wen and Wu, Yu and Weng, Xiangqin and Song, Jiachun and Yan, Ni and Ye, Chenjing and Shi, Fangfang and Cui, Jingyi and Zheng, Derun and Zhang, Hesong and Tan, Kai and Chen, Xueqin and Zhang, Sujiang and Wu, Jiale and Lu, Min},
  title = {Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {862},
  doi = {10.1126/scitranslmed.ads9325}
}
Kostenlos starten →